查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
疫苗合同製造市場 - 增長、未來展望、競爭分析，2023-2031 年
市場調查報告書
商品編碼
1255984

疫苗合同製造市場 - 增長、未來展望、競爭分析，2023-2031 年

Vaccine Contract Manufacturing Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

隨著疫苗品種的豐富和需求的不斷增長，疫苗合同製造市場與每個地區的主要公司競爭激烈。 除了疫苗的安全性和有效性外，將我們自己的產品推向市場也很重要。 為了滿足對疫苗不斷增長的需求並保持統一的質量，大公司傾向於將疫苗生產外包給第三方，以便更快地進入市場。

各地區疫苗接種意識的提高有助於疫苗合同製造整個市場的增長。 此外，政府在世界範圍內強制接種疫苗的努力導致對疫苗的需求增加。 世界衛生組織 (WHO) 的全球疫苗行動計劃 (GVAP) 是一項旨在通過到 2020 年增加疫苗接種率來預防死亡的倡議。 截至 2017 年 5 月，194 個衛生部批准了一項加強免疫的新舉措，以實現全球疫苗行動計劃的目標。 據世界衛生組織稱，全球約有 1950 萬嬰兒仍未接種所需的疫苗。 隨著對疫苗的需求不斷增加，以及現有企業主要專注於開發其他分子，他們中的大多數選擇外包。 新興市場還缺乏足夠的製造設施和熟練勞動力，需要承包外包製造以滿足市場標準。

疫苗合同製造商遵守良好生產規範 (GMP) 並提供審查文件以確保質量。 隨著疫苗製造的新進展，合同製造商不斷升級他們的製造設施以提供最新的服務。 在行業領導者的初始開發過程中，與第三方接觸以擴展該過程。

持續的合作夥伴關係和收購將進一步加速整體市場增長。 2017 年 10 月，DCPrime BV 與 apceth Biopharma GmbH 的合同製造商合作，開發了一種用於治療癌症的樹突狀細胞疫苗。 該合作夥伴關係將包括臨床批量生產和癌症疫苗大規模生產工藝的開發。 然而，一些大型製藥公司更願意在內部生產疫苗，以避免管理突發事件和安全性和有效性偏差的風險。 在預測期內，這一因素可能會對全球採用基於合同的服務產生負面影響。

內容

第一章前言

  • 報告內容
    • 報告的目的
    • 目標受眾
    • 主要產品
  • 市場細分
  • 調查方法
    • 第一階段 - 二次調查
    • 第二階段 - 初步研究
    • 第三階段 - 專家評審
    • 先決條件
    • 採用的方法

第 2 章執行摘要

  • 市場概況：全球疫苗合同製造市場
  • 全球疫苗合同製造市場：按服務分類，2022 年
  • 全球疫苗合同製造市場：按應用分類，2022 年
  • 全球疫苗合同製造市場：按地區劃分，2022 年
  • 有吸引力的投資建議：按地區劃分，2022 年

第 3 章疫苗合同製造市場：競爭分析

  • 主要供應商的市場定位
  • 供應商採用的策略
  • 主要產業戰略
  • 等級分析：2022 年與 2031 年

第 4 章疫苗合同製造市場：宏觀分析和市場動態

  • 介紹
  • 2021-2031 年全球疫苗合同製造市場價值
  • 市場動態
    • 市場驅動因素
    • 市場製約因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析

第 5 章疫苗合同製造市場：按服務分類，2021-2031

  • 市場概覽
  • 增長和收益分析：2022 年與 2031 年
  • 市場細分
    • 細胞系/菌株開發
    • 上游流程開發
    • 下游流程開發
    • 分析開發
    • 穩定性測試
    • 產品發布

第 6 章疫苗合同製造市場：按應用 2021-2031

  • 市場概覽
  • 增長和收益分析：2022 年與 2031 年
  • 市場細分
    • 人類使用
    • 獸醫

第 7 章北美疫苗合同製造市場 2021-2031

  • 市場概覽
  • 疫苗合同製造市場：按服務分類，2021-2031 年
  • 疫苗合同製造市場：2021-2031 年（按應用）
  • 疫苗合同製造市場：地區 2021-2031
    • 北美
      • 美國
      • 加拿大
      • 其他北美地區

第 8 章英國和歐盟疫苗合同製造市場 2021-2031

  • 市場概覽
  • 疫苗合同製造市場：按服務分類，2021-2031 年
  • 疫苗合同製造市場：2021-2031 年（按應用）
  • 疫苗合同製造市場：地區 2021-2031
    • 英國和歐盟
      • 英國
      • 德國
      • 西班牙
      • 意大利
      • 法國
      • 其他歐洲地區

第 9 章亞太疫苗合同製造市場 2021-2031

  • 市場概覽
  • 疫苗合同製造市場：按服務分類，2021-2031 年
  • 疫苗合同製造市場：2021-2031 年（按應用）
  • 疫苗合同製造市場：地區 2021-2031
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區

第 10 章拉丁美洲疫苗合同製造市場 2021-2031

  • 市場概覽
  • 疫苗合同製造市場：按服務分類，2021-2031 年
  • 疫苗合同製造市場：2021-2031 年（按應用）
  • 疫苗合同製造市場：地區 2021-2031
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地區

第 11 章中東和非洲疫苗合同製造市場 2021-2031

  • 市場概覽
  • 疫苗合同製造市場：按服務分類，2021-2031 年
  • 疫苗合同製造市場：2021-2031 年（按應用）
  • 疫苗合同製造市場：地區 2021-2031
    • 中東和非洲
      • 海灣合作委員會
      • 非洲
      • 其他中東和非洲地區

第12章公司簡介

  • Ajinomoto Althea Inc.
  • Albany Molecular Research Inc.
  • Cobra Biologics & Pharmaceutical Services
  • Cytovance Biologics
  • Catalent Inc.
  • FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
  • ICON plc.
  • IDT Biologika GmbH
  • Lonza Group Ltd.
  • Merck KGaA
  • Paragon Bioservices Inc.
  • PRA Health Sciences
  • Others notable players
Product Code: 137988-01-23

An extensive portfolio of vaccines and constant rising demand has rendered the vaccine contract manufacturing market to be highly competitive with vast presence of key players across geographies. Along with safety and effectiveness of vaccines, flooding the market with one's product clutches equal importance. In order to cater to the rising demand for vaccines and maintaining uniform quality, leading industrial players tend to outsource manufacturing of vaccines to third parties to expedite market entry.

Rising awareness of immunization across geographies contributes to the overall market growth of vaccine contract manufacturing. Additionally, government initiatives enforcing immunization globally has led to rising vaccine demand. The Global Vaccine Action Plan (GVAP) by the World Health Organization (WHO) is an initiative to prevent deaths via expanding the access of vaccines by 2020. As of May 2017, Health ministries across 194 countries endorsed a new initiative on strengthening immunization to meet the goals of GVAP. As per the WHO, around 19.5 million infants worldwide were still not provided with necessary vaccines. The ever-rising need for vaccines, and with established players primarily focusing on the development of other molecules, outsourcing is mostly the preferred choice. Additionally, in developing nations, the lack of suitable manufacturing set up and skilled labour compels them to engage with contract manufacturers in order to cater to market standards.

Vaccine contract manufacturers comply with the Good Manufacturing Practices and provide concerned quality assurance review documents. With newer advancements in vaccine production, the contract vendors constantly upgrade their production facilities providing up-to-date services. With initial development process taking place by industrial leaders, third parties are approached for scaling up processes.

Continuous partnerships and acquisitions further catalyse the overall market growth. In October 2017, DCPrime BV a firm developing dendritic cell vaccines for cancer therapy collaborated with apceth Biopharma GmbH contract manufacturer. The collaboration comprises clinical batch production and the development of an expanded scale manufacturing process for cancer vaccines. However, a few large pharmaceutical firms prefer to maintain vaccine manufacturing in-house to avoid risks of management contingencies and deviation in safety and efficacy. This factor could have a negative impact on the global adoption of contract-based services during the forecast period.

Rising demand for expedited entry of vaccines into the market has rendered the vaccine contract manufacturing market to be highly competitive with a vast outreach across geographies. The key industrial players enjoying a dominant position in this market are Ajinomoto Althea, Inc., Albany Molecular Research, Inc., Cobra Biologics & Pharmaceutical Services, Cytovance Biologics; Catalent, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON plc., IDT Biologika GmbH, Lonza Group, Ltd., Merck KGaA, Paragon Bioservices, Inc., PRA Health Sciences and Others notable players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Vaccine Contract Manufacturing market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Vaccine Contract Manufacturing market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Service

Cell line/strain development

Upstream process development

Downstream process development

Analytical development

Stability testing

Product release

Application

Human use

Veterinary

Region Segment (2021-2031; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Vaccine Contract Manufacturing market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Vaccine Contract Manufacturing market?

Which is the largest regional market for Vaccine Contract Manufacturing market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Vaccine Contract Manufacturing market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Vaccine Contract Manufacturing market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Vaccine Contract Manufacturing Market
  • 2.2. Global Vaccine Contract Manufacturing Market, By Service, 2022 (US$ Million)
  • 2.3. Global Vaccine Contract Manufacturing Market, By Application, 2022 (US$ Million)
  • 2.4. Global Vaccine Contract Manufacturing Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Vaccine Contract Manufacturing Market: Competitive Analysis

  • 3.1. Market Positioning of Key Vaccine Contract Manufacturing Market Vendors
  • 3.2. Strategies Adopted by Vaccine Contract Manufacturing Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Vaccine Contract Manufacturing Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Vaccine Contract Manufacturing Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Cell line/strain development
    • 5.3.2. Upstream process development
    • 5.3.3. Downstream process development
    • 5.3.4. Analytical development
    • 5.3.5. Stability testing
    • 5.3.6. Product release

6. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Human use
    • 6.3.2. Veterinary

7. North America Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
  • 7.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 7.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 7.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 7.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 7.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

8. UK and European Union Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
  • 8.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 8.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.4.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.5.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.6.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

9. Asia Pacific Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
  • 9.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 9.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.4.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.5.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.6.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

10. Latin America Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
  • 10.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 10.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 10.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 10.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 10.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

11. Middle East and Africa Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
  • 11.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 11.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 11.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 11.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 11.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. Ajinomoto Althea, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Albany Molecular Research, Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Cobra Biologics & Pharmaceutical Services
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Cytovance Biologics
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Catalent, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. ICON plc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. IDT Biologika GmbH
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Lonza Group, Ltd.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Merck KGaA
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Paragon Bioservices, Inc.
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. PRA Health Sciences
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives
  • 12.13. Others notable players
    • 12.13.1. Company Overview
    • 12.13.2. Financial Performance
    • 12.13.3. Product Portfolio
    • 12.13.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 2 Global Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 3 North America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 4 North America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 5 U.S. Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 6 U.S. Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 7 Canada Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 8 Canada Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 9 Rest of North America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 10 Rest of North America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 11 UK and European Union Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 12 UK and European Union Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 13 UK Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 14 UK Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 15 Germany Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 16 Germany Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 17 Spain Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 18 Spain Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 19 Italy Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 20 Italy Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 21 France Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 22 France Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 23 Rest of Europe Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 24 Rest of Europe Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 25 Asia Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 26 Asia Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 27 China Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 28 China Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 29 Japan Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 30 Japan Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 31 India Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 32 India Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 33 Australia Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 34 Australia Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 35 South Korea Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 36 South Korea Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 37 Latin America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 38 Latin America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 39 Brazil Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 40 Brazil Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 41 Mexico Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 42 Mexico Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 43 Rest of Latin America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 44 Rest of Latin America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 45 Middle East and Africa Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 46 Middle East and Africa Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 47 GCC Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 48 GCC Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 49 Africa Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 50 Africa Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Vaccine Contract Manufacturing Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Vaccine Contract Manufacturing Market: Quality Assurance
  • FIG. 5 Global Vaccine Contract Manufacturing Market, By Service, 2022
  • FIG. 6 Global Vaccine Contract Manufacturing Market, By Application, 2022
  • FIG. 7 Global Vaccine Contract Manufacturing Market, By Geography, 2022
  • FIG. 8 Market Geographical Opportunity Matrix - Global Vaccine Contract Manufacturing Market, 2022
  • FIG. 9 Market Positioning of Key Vaccine Contract Manufacturing Market Players, 2022
  • FIG. 10 Global Vaccine Contract Manufacturing Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
  • FIG. 11 Global Vaccine Contract Manufacturing Market, By Service, 2022 Vs 2031, %
  • FIG. 12 Global Vaccine Contract Manufacturing Market, By Application, 2022 Vs 2031, %
  • FIG. 13 U.S. Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 14 Canada Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 15 Rest of North America Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 16 UK Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 17 Germany Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 18 Spain Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 19 Italy Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 20 France Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of Europe Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 22 China Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 23 Japan Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 24 India Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 25 Australia Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 26 South Korea Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Asia Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 28 Brazil Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 29 Mexico Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 30 Rest of Latin America Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 31 GCC Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 32 Africa Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Middle East and Africa Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031